Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C55H86O24 |
| Molecular Weight | 1131.2569 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 27 / 27 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]8(O[C@H]1[C@H](O)[C@@H](O[C@]2([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@]([H])(O[C@H]3CC[C@@]4(C)[C@@]([H])(CC[C@]5(C)[C@]4([H])CC=C6[C@]7([H])CC(C)(C)[C@@H](OC(=O)C(\C)=C/C)[C@H](O)[C@]7(COC(C)=O)[C@H](O)C[C@@]56C)[C@@]3(C)CO)O[C@@H]1C(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O
InChI
InChIKey=YOSIWGSGLDDTHJ-OXPBSUTMSA-N
InChI=1S/C55H86O24/c1-10-23(2)46(71)79-44-43(68)55(22-72-24(3)59)26(17-50(44,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)60)75-49-41(77-48-38(66)36(64)34(62)28(20-57)74-48)39(67)40(42(78-49)45(69)70)76-47-37(65)35(63)33(61)27(19-56)73-47/h10-11,26-44,47-49,56-58,60-68H,12-22H2,1-9H3,(H,69,70)/b23-10-/t26-,27+,28+,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42-,43-,44-,47-,48-,49+,51-,52+,53+,54+,55-/m0/s1
| Molecular Formula | C55H86O24 |
| Molecular Weight | 1131.2569 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 27 / 27 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: doi:10.1248/cpb.52.1246https://www.ncbi.nlm.nih.gov/pubmed/22094055Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24334163
Sources: doi:10.1248/cpb.52.1246https://www.ncbi.nlm.nih.gov/pubmed/22094055
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24334163
Escin Ia and isoescin Ia have been traditionally used clinically as the chief active ingredients of escin, a major triterpene saponin isolated from horse chestnut (Aesculus hippocastanum) seeds for the treatment of chronic venous insufficiency, hemorrhoids, inflammation and edema. The interconversion of escin Ia and isoescin Ia when given alone indicates that administration of one isomer leads to exposure to the other.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Anti-HIV-1 protease triterpenoid saponins from the seeds of Aesculus chinensis. | 1999 Nov |
|
| Determination of four major saponins in the seeds of Aesculus chinensis Bunge using accelerated solvent extraction followed by high-performance liquid chromatography and electrospray-time of flight mass spectrometry. | 2007 Jul 23 |
|
| Simultaneous analysis of isomers of escin saponins in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration. | 2010 Apr 1 |
|
| Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats. | 2014 Feb 3 |
|
| Determination of Four Major Saponins in Skin and Endosperm of Seeds of Horse Chestnut (Aesculus Hippocastanum L.) Using High Performance Liquid Chromatography with Positive Confirmation by Thin Layer Chromatography. | 2015 Nov |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:16:08 GMT 2023
by
admin
on
Sat Dec 16 11:16:08 GMT 2023
|
| Record UNII |
63505RAS3F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
219944-46-4
Created by
admin on Sat Dec 16 11:16:08 GMT 2023 , Edited by admin on Sat Dec 16 11:16:08 GMT 2023
|
PRIMARY | |||
|
63505RAS3F
Created by
admin on Sat Dec 16 11:16:08 GMT 2023 , Edited by admin on Sat Dec 16 11:16:08 GMT 2023
|
PRIMARY | |||
|
6476033
Created by
admin on Sat Dec 16 11:16:08 GMT 2023 , Edited by admin on Sat Dec 16 11:16:08 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
